Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantFV
Future Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
Future Ventures is the investment firm associated with Steve Jurvetson and Maryanna Saenko, identified by Modulate and in its own Moonwalk news.
Recorded funding activity
Modulate develops models that analyze voice conversations beyond transcripts. Moonwalk develops fat-tissue-targeted medicines, while Shennon develops cancer immunotherapies. These relationships identify the firm separately from the unrelated Indian namesake.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $82M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMoonwalk Biosciences
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
$70MSeries B
Participant